Electronic Theses and Dissertations

Date of Award


Document Type


Degree Name

M.S. in Pharmaceutical Science


Pharmaceutics and Drug Delivery

First Advisor

Soumyajit Majumdar

Second Advisor

Eman Ashour

Third Advisor

Michael A. Repka

Relational Format



Cyclosporine (CSA) is a highly potent immunosuppressant drug and has been used to treat rheumatoid arthritis, psoriasis, organ rejection post-transplant, and chronic dry eye disease. The objective of this investigation was to increase the CSA residence time on the ocular surface using solid lipid nanoparticles (SLNs) and its in-situ gel formulation (CSA-SLN-IG), for treatment of dry eye disease. CSA loaded SLNs (CSA-SLN) were prepared with the homogenization method, using Precirol ® ATO 5 as a solid lipid and Tween® 80 and Poloxamer 188 as surfactants. Prepared SLNs were optimized based on particle size, zeta potential (ZP), PDI, assay and stability. CSA-SLN in-situ gels (CSA-SLN-IG) were developed using gellan gum as the gelling agent and rheological properties were evaluated. DSC analysis shothat there was no interaction between lipid and drug. Optimized CSA-SLN shothe particle size, PDI, ZP and assay to be121.20± 5.20 nm, 0.4 ±0.04, -24 ± 1, 95 ± 0.5% respectively. CSA-SLN was stable at refrigerated and room temperature conditions over one month and no significant changes were observed before and after autoclaving up to one month. CSA-SLN-IG prepared with 0.3% gellan gum shoimmediate gel formation with a gel residence time of more than 24 hours, the viscosity of 27.90± 2.80 cP and an assay of 85 ± 0.5%.Therefore, CSA-SLN and CSA-SLN-IG could be considered as an alternative approach for dry eye disease.


To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.